Clinical trial NCT03638375: TIL and Anti-PD1 in Metastatic Melanoma
Official title: Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Toxicity, Drug
Adverse Drug Event
Effects of Immunotherapy
Keywords: Metastatic melanoma
anti-PD1
TIL
interferon-alpha
adoptive cell therapy
nivolumab
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
First posted: 2018-08-20
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The ACTME trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.

Phase 1, Cohort 1: Adding TIL therapy to anti-PD1 immunotherapy. Phase 1, Cohort 2: Adding IFN-alpha to the treatment with TIL and anti-PD1 immunotherapy.

Phase 2: Patients will be treated with TIL, IFN-alpha and anti-PD1 according to the same schedule as used in phase 1 cohort 2.
Primary purpose: TREATMENT

Brief summary: The ACTME study is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma. The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL. The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe.

Detailed description: The ACTME is an investigator initiated, single center phase I/II clinical trial for patients with progressive unresectable stage III or stage IV melanoma.

Patients are conditioned by low-dose IFN-alpha and treated with ACT and PD-1 antibodies. With this approach the investigators hope to solve 4 of the most important aspects curtailing the efficacy of current immunotherapies in metastatic melanoma:

1. the lack of sufficient numbers of activated tumor-reactive T cells in patients by providing ACT; and
2. the inhibition of T-cell effector function through PD-1 signalling by administration of nivolumab; as well as
3. the toxicity of high-dose IL-2, and
4. long term hospitalization of patients due to the conditioning-regimen used in most ACT protocols by replacing it with low-dose IFN-alpha treatment.

The trial consists of both a phase I part to determine safety and feasibility and a phase II part to evaluate first clinical activity of IFN-alpha, nivolumab and TIL.

The treatment with IFN-alpha will be added after the combination of TIL and nivolumab has proven to be safe in the first cohort of the phase I part of the trial.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years
2. Histologically or cytologically proven metastatic skin melanoma
3. Melanoma must be at one of the following AJCC 2009 stages:

   * Unresectable (or residual) regional metastatic melanoma, i.e. in terms of AJCC 2009 classification unresectable stage III melanoma, or
   * Stage IV melanoma, i.e. distant metastatic disease (any T, any N, M1a, M1b or M1c), and normal LDH
   * Patients have failed on standard treatment options
4. Patients with brain metastases have to be neurologically stable for at least 2 months and should not use dexamethasone
5. Presence of measurable progressive disease according to RECIST version 1.1
6. Expected survival of at least 3 months
7. WHO performance status ≤1
8. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified:

   Lab Parameter Range Hemoglobin ≥ 6,0 mmol/l Granulocytes ≥ 1,500/µl Lymphocytes ≥ 700/µl Platelets ≥ 100,000/µl Creatinine clearance ≥ 60 min/ml Serum bilirubin ≤ 40 µmol/l ASAT and ALAT ≤ 5 x the normal upper limit LDH ≤ 2 x the normal upper limit
9. Viral tests must be performed at least 30 days before surgery:

   * Negative for HIV type 1/2, HTLV and TPHA
   * No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum
   * No antibodies against HCV (hepatitis C virus) in the serum
10. Able and willing to give valid written informed consent.
11. Progressive disease on prior treatment with f.e. BRAF-inhibitors, MEK-inhibitors or immunotherapy, including anti-PD1 treatment. Systemic therapy must have been discontinued for at least four weeks before start of study treatment.

Exclusion Criteria:

1. Patients with brain metastases who are neurologically unstable and/or use dexamethasone
2. Clinically significant heart disease (NYHA Class III or IV)
3. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study
4. Active immunodeficiency disease, autoimmune disease requiring immune suppressive drugs or autoimmune adverse events following treatment with checkpoint inhibitors. Vitiligo is not an exclusion criterion
5. Subjects with a condition requiring systemic chronic steroid therapy (≥ 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 14 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids, and adrenal replacement therapy are allowed.
6. Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical carcinoma
7. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
8. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the associated with the participation, study drug administration, or would impair the ability of the patient to receive protocol therapy
9. Lack of availability for follow-up assessments
10. Pregnancy or breastfeeding
11. Known allergy to penicillin or streptomycin (used during the culturing of T cells)

Primary outcomes:
measure: Incidence of treatment-related serious adverse events as assessed by CTCAE 4.0 criteria
timeFrame: 14 weeks after start of treatment
Secondary outcomes:
measure: Evaluation of disease control rate according to RECIST 1.1 criteria
timeFrame: 14 weeks after first nivolumab infusion
measure: Evaluation of disease control rate according to immune RECIST response criteria
timeFrame: 14 weeks after first nivolumab infusion
measure: To study the potential working mechanisms of the different treatment compounds. Therefore, blood will be drawn to analyse changes in circulating immune cells and their function during treatment.
timeFrame: Within 5 years after first inclusion
measure: To establish a possible prognostic biomarker profile in patients tumor material, blood, serum and TILs used for infusion
timeFrame: Within 5 years after first inclusion
measure: To characterize the infusion product
timeFrame: Within 5 years after first inclusion
measure: To analyse potential correlations between the clinical response and hypothesis related immune parameters
timeFrame: Within 5 years after first inclusion
measure: To analyse the overall survival following treatment
timeFrame: Within 5 years after first inclusion
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
Study officials:
affiliation: LUMC
name: Ellen Kapiteijn, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036.